Liver cancer study seeks clues in immune cells to predict immunotherapy success
NCT ID NCT05044676
First seen Dec 24, 2025 · Last updated May 10, 2026 · Updated 14 times
Summary
This study aimed to see if certain immune cell markers could predict which patients with advanced liver cancer would respond to a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). Researchers planned to measure these markers before and after treatment in about 4 participants. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière
Paris, France, 75013, France
Conditions
Explore the condition pages connected to this study.